생물학적 제제 CRO 시장 규모, 점유율, 동향 분석 보고서 : 종류별, 제품별, 서비스별, 치료 분야별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Biologics Contract Research Organizations Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Pre-clinical, And Clinical), By Product, By Service, By Therapeutic Area, By End Use, By Region, And Segment Forecasts, 2025 - 2033

US $ 5,950 ￦ 8,858,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,347,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,324,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

생물학적 제제 CRO 시장 : 개요

세계의 생물학적 제제 CRO(의약품 임상시험수탁기관) 시장 규모는 2024년에 136억 6,000만 달러로 추정되며, 2033년까지 323억 달러에 달할 것으로 예측됩니다.

2025년부터 2033년까지 10.17%의 CAGR을 기록할 것으로 예상됩니다. 시장 성장의 주요 요인으로는 생물학적 제제에 대한 수요 증가, 제약기업의 아웃소싱 트렌드 증가, 맞춤형 의료 및 세포 및 유전자 치료에 대한 요구 확대 등을 꼽을 수 있습니다.

그 외 시장 성장요인으로는 임상시험 관리 분야의 기술 발전의 가속화, 바이오제약 기업에서 CRO의 전문적 지식의 필요성을 강조하는 엄격한 규제 요건을 들 수 있습니다.

전 세계 바이오의약품 CRO 시장에서는 단클론항체, 백신, 세포 및 유전자 치료제를 포함한 생물학적 제제에 대한 수요가 증가하고 있습니다. 이러한 복잡한 분자의 대부분은 전문적인 연구, 임상시험, 규제에 대한 전문 지식이 필요하지만, 많은 제약사들은 이러한 역량을 사내에 보유하고 있지 않습니다. 이러한 요인으로 인해 생물학적 제제에 특화된 시험 설계, 생물학적 시험, 제조 지원을 제공하는 CRO 서비스의 필요성이 증가하고 있으며, 개발 기간 단축, 비용 절감, 고품질 데이터 확보를 촉진하고 있습니다. CRO는 확대되는 생물학적 제제 파이프라인을 추진하는 스폰서에게 없어서는 안 될 파트너가 되고 있습니다. 이러한 추세는 치료제 분야에서 두드러지게 나타나고 있으며, CRO의 전문성과 인프라는 임상 결과의 성공에 필수적입니다.

또한, 시장 성장에 기여하는 또 다른 요인으로는 임상시험 관리 분야의 기술 발전이 가속화되고 있다는 점을 들 수 있습니다. 이는 생물제제 CRO의 업무 운영을 변화시키고 있습니다. AI, 머신러닝, 데이터 분석의 통합을 통해 환자 모집 가속화, 예측 모델링, 임상시험 데이터의 실시간 모니터링이 가능해집니다. 또한, 디지털 플랫폼, 전자 데이터 수집(EDC), 분산형 테스트 솔루션은 효율성, 투명성, 컴플라이언스를 더욱 향상시켜 시장 성장을 견인할 것으로 예상됩니다. 자동화와 첨단 바이오인포매틱스는 복잡한 생물학적 제제 연구에서 데이터 처리의 효율성을 더욱 높여줍니다. 이러한 기술은 오류 감소, 의사결정 개선, 시험 일정 단축을 지원합니다. 따라서 생물학적 제제 연구가 점점 더 데이터 집약적이 되면서 대부분의 CRO는 복잡성을 관리하고, 시험 결과를 최적화하며, 혁신적인 치료법을 신속하게 시장에 출시할 수 있도록 스폰서를 지원하기 위해 기술 주도형 솔루션을 선택하고 있습니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 생물학적 제제 CRO 시장 : 변수, 동향, 범위

• 시장 연관 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
• 기술 동향
• 가격 모델 분석
• 관세 영향 분석
• 밸류체인 분석
  • 공급 동향
  • 수요 동향
• 시장 분석 툴
  • Porter's Five Forces 분석
  • SWOT에 의한 PESTEL 분석

제4장 생물학적 제제 CRO 시장 : 종류별 추정·동향 분석

• 생물학적 제제 CRO 시장 : 변동 분석, 종류별
• 생물학적 제제 CRO 시장, 추정치·예측치 : 종류별(2021-2033년)
• Drug Discovery
  • 표적 검증
  • 리드 화합물 동정
  • 리드 최적화
• 전임상
• 임상
  • 제I상 임상시험 서비스
  • 제II상 임상시험 서비스
  • 제III상 임상시험 서비스
  • 제IV상 임상시험 서비스

제5장 생물학적 제제 CRO 시장 : 제품별 추정·동향 분석

• 생물학적 제제 CRO 시장 : 변동 분석, 제품별
• 생물학적 제제 CRO 시장, 추정치·예측치 : 제품별(2021-2033년)
• 단클론항체(mAb)
• 항체약물접합체(ADC)
• 이중특이성/다중특이성 항체
• 재조합 단백질 및 효소
• 백신
• 세포 및 유전자 치료
• 핵산 기반 치료제
• 기타

제6장 생물학적 제제 CRO 시장 : 서비스별 추정·동향 분석

• 생물학적 제제 CRO 시장 : 변동 분석, 서비스별
• 생물학적 제제 CRO 시장, 추정치·예측치 : 서비스별(2021-2033년)
• 프로젝트 관리/임상 공급 관리
• 데이터 관리
• 규제/MA(Medical Affairs)
• 메디컬 라이팅
• 임상 모니터링
• 품질 관리/품질 보증
• 바이오 통계
• 임상시험 책임 의사에게 지급
• 검사실
  • 무균 시험
  • 용기·봉지 시험
  • 추출물 및 용출물 시험
  • 환경 모니터링(미생물학적 시험을 포함)
  • 소독제 유효성 시험
  • 기타
• 환자·시설 모집
• 기술
• 기타

제7장 생물학적 제제 CRO 시장 : 치료 분야별 추정·동향 분석

• 생물학적 제제 CRO 시장 : 변동 분석, 치료 분야별
• 생물학적 제제 CRO 시장, 추정치·예측치 : 치료 분야별(2021-2033년)
• 종양
• 중추신경계 질환
• 감염증
• 면역질환
• 순환기질환
• 호흡기질환
• 당뇨병
• 안과
• 통증 관리
• 기타

제8장 생물학적 제제 CRO 시장 : 최종 용도별 추정·동향 분석

• 생물학적 제제 CRO 시장 : 변동 분석, 최종 용도별
• 생물학적 제제 CRO 시장, 추정치·예측치 : 최종 용도별(2021-2033년)
• 주요 바이오의약품 기업
• 중소 바이오의약품 기업
• 기타

제9장 생물학적 제제 CRO 시장 : 지역별 추정·동향 분석

• 시장 대시보드 : 지역별
• 시장 점유율 분석 : 지역별(2024년·2033년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 아랍에미리트
  • 사우디아라비아
  • 쿠웨이트
  • 카타르
  • 오만

제10장 경쟁 구도

• 주요 진출 기업의 분류
  • 시장 리더
  • 신흥 기업
• 시장 점유율/평가 분석(히트맵 분석, 2024년)
• 기업 개요
  • Lonza Group AG
  • WuXi Biologics/WuXi AppTec
  • Samsung Biologics
  • Catalent, Inc.
  • Fujifilm Diosynth Biotechnologies
  • AGC Biologics
  • Thermo Fisher Scientific(Patheon)
  • Boehringer Ingelheim(BioXcellence)
  • Charles River Laboratories
  • Parexel International
  • IQVIA
  • Medpace Holdings, Inc.
  • Syngene International
  • Eurofins Scientific
  • KBI Biopharma

KSM

영문 목차

영문목차

Biologics Contract Research Organizations Market Summary

The global biologics contract research organizations market size was estimated at USD 13.66 billion in 2024 and is projected to reach USD 32.30 billion by 2033, growing at a CAGR of 10.17% from 2025 to 2033. The market growth is driven by rising demand for biologics, increasing outsourcing trends among pharmaceutical companies, growing requirements for personalized medicine, and cell & gene therapies.

Other factors contributing to market growth include rising technological advancements in clinical trial management and stringent regulatory requirements that underscore the need for specialized CRO expertise among biopharmaceutical companies.

In the global biologics contract research organizations (CRO) market, the CRO are experiencing growing demand for biologics, including monoclonal antibodies, vaccines, and cell & gene therapies. Most of these complex molecules require specialized research, clinical trials, and regulatory expertise that many pharmaceutical companies lack in-house. Thus, these factors have led to a growing need for CRO services, as they offer biologics-focused trial design, bioanalytical testing, and manufacturing support, further accelerating development timelines, reducing costs, and ensuring high-quality data, making them indispensable partners for sponsors navigating the expanding biologics pipeline. This trend is emerging in the therapies, where CROs' specialized knowledge and infrastructure are critical for successful clinical outcomes.

Moreover, other factors contributing to market growth include rising technological advancements in clinical trial management, which are transforming the operations within biologics CROs. Integrating AI, machine learning, and data analytics further enables faster patient recruitment, predictive modeling, and real-time monitoring of clinical trial data. Furthermore, digital platforms, electronic data capture (EDC), and decentralized trial solutions further enhance efficiency, transparency, and compliance, which are expected to drive market growth. Automation and advanced bioinformatics further streamline data handling for complex biologics studies. These technologies support reducing errors, improving decision-making, and accelerating trial timelines. Thus, as biological research becomes increasingly data-intensive, most CROs opt for technology-driven solutions to manage complexity, optimize trial outcomes, and support sponsors in bringing innovative therapies to market faster.

Global Biologics Contract Research Organizations Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biologics contract research organizations market report based on type, product, service, therapeutic area, end use, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery
  • Target Validation
  • Lead Identification
  • Lead Optimization
• Pre-Clinical
• Clinical
  • Phase I Trial Services
  • Phase II Trial Services
  • Phase III Trial Services
  • Phase IV Trial Services
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Monoclonal Antibodies (mAbs)
• Antibody-Drug Conjugates (ADCs)
• Bispecific/Multispecific Antibodies
• Recombinant Proteins & Enzymes
• Vaccines
• Cell & Gene Therapies
• Nucleic Acid-Based Therapeutics
• Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Project Management/Clinical Supply Management
• Data Management
• Regulatory/Medical Affairs
• Medical Writing
• Clinical Monitoring
• Quality Management/ Assurance
• Bio-Statistics
• Investigator Payments
• Laboratory
  • Sterility Testing
  • Container/Closure Testing
  • Extractables and Leachable Testing
  • Environmental Monitoring (Including Microbiology Testing)
  • Disinfectant Efficacy Studies
  • Others
• Patient And Site Recruitment
• Technology
• Others
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• CNS Disorders
• Infectious Diseases
• Immunological Disorders
• Cardiovascular Diseases
• Respiratory Diseases
• Diabetes
• Ophthalmology
• Pain Management
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Large Biopharmaceutical Companies
• Small & Mid-Sized Biopharmaceutical Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Product
  • 1.2.3. Service
  • 1.2.4. Therapeutic Area
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Biologics Contract Research Organizations (CRO) Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Biologics Contract Research Organizations (CRO) Market: Type Estimates & Trend Analysis

• 4.1. Biologics Contract Research Organizations (CRO) Market, By Type: Segment Dashboard
• 4.2. Biologics Contract Research Organizations (CRO) Market, By Type: Movement Analysis
• 4.3. Biologics Contract Research Organizations (CRO) Market Estimates & Forecasts, By Type, 2021 - 2033 (USD Million)
• 4.4. Drug Discovery
  • 4.4.1. Drug Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Target Validation
    • 4.4.2.1. Target Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Lead Identification
    • 4.4.3.1. Lead Identification Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Lead Optimization
    • 4.4.4.1. Lead Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Pre-Clinical
  • 4.5.1. Pre-Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Clinical
  • 4.6.1. Clinical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Phase I Trial Services
    • 4.6.2.1. Phase I Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Phase II Trial Services
    • 4.6.3.1. Phase II Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Phase III Trial Services
    • 4.6.4.1. Phase III Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6.5. Phase IV Trial Services
    • 4.6.5.1. Phase IV Trial Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Biologics Contract Research Organizations (CRO) Market: Product Estimates & Trend Analysis

• 5.1. Biologics Contract Research Organizations (CRO) Market, By Product: Segment Dashboard
• 5.2. Biologics Contract Research Organizations (CRO) Market, By Product: Movement Analysis
• 5.3. Biologics Contract Research Organizations (CRO) Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 5.4. Monoclonal Antibodies (mAbs)
  • 5.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Antibody-Drug Conjugates (ADCs)
  • 5.5.1. Antibody-Drug Conjugates (ADCs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Bispecific/Multispecific Antibodies
  • 5.6.1. Bispecific/Multispecific Antibodies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Recombinant Proteins & Enzymes
  • 5.7.1. Recombinant Proteins & Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Vaccines
  • 5.8.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Cell & Gene Therapies
  • 5.9.1. Cell & Gene Therapies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.10. Nucleic Acid-Based Therapeutics
  • 5.10.1. Nucleic Acid-Based Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.11. Others
  • 5.11.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Biologics Contract Research Organizations (CRO) Market: Service Estimates & Trend Analysis

• 6.1. Biologics Contract Research Organizations (CRO) Market, By Service: Segment Dashboard
• 6.2. Biologics Contract Research Organizations (CRO) Market, By Service: Movement Analysis
• 6.3. Biologics Contract Research Organizations (CRO) Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 6.4. Project Management/Clinical Supply Management
  • 6.4.1. Project Management/Clinical Supply Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Data Management
  • 6.5.1. Data Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Regulatory/Medical Affairs
  • 6.6.1. Regulatory/Medical Affairs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Medical Writing
  • 6.7.1. Medical Writing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Clinical Monitoring
  • 6.8.1. Clinical Monitoring Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Quality Management/ Assurance
  • 6.9.1. Quality Management/ Assurance Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.10. Bio-Statistics
  • 6.10.1. Bio-Statistics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.11. Investigator Payments
  • 6.11.1. Investigator Payments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.12. Laboratory
  • 6.12.1. Laboratory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12.2. Sterility Testing
    • 6.12.2.1. Sterility Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12.3. Container/Closure Testing
    • 6.12.3.1. Container/Closure Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12.4. Extractables and Leachable Testing
    • 6.12.4.1. Extractables and Leachable Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12.5. Environmental Monitoring (Including Microbiology Testing)
    • 6.12.5.1. Environmental Monitoring (Including Microbiology Testing) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12.6. Disinfectant Efficacy Studies
    • 6.12.6.1. Disinfectant Efficacy Studies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12.7. Others
    • 6.12.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.13. Patient And Site Recruitment
  • 6.13.1. Patient And Site Recruitment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.14. Technology
  • 6.14.1. Technology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.15. Others
  • 6.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Biologics Contract Research Organizations (CRO) Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Biologics Contract Research Organizations (CRO) Market, By Therapeutic Area: Segment Dashboard
• 7.2. Biologics Contract Research Organizations (CRO) Market, By Therapeutic Area: Movement Analysis
• 7.3. Biologics Contract Research Organizations (CRO) Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033 (USD Million)
• 7.4. Oncology
  • 7.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. CNS Disorders
  • 7.5.1. CNS Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Infectious Diseases
  • 7.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Immunological Disorders
  • 7.7.1. Immunological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Cardiovascular Diseases
  • 7.8.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Respiratory Diseases
  • 7.9.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Diabetes
  • 7.10.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.11. Ophthalmology
  • 7.11.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.12. Pain Management
  • 7.12.1. Pain Management Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.13. Others
  • 7.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Biologics Contract Research Organizations (CRO) Market: End Use Estimates & Trend Analysis

• 8.1. Biologics Contract Research Organizations (CRO) Market, By End Use: Segment Dashboard
• 8.2. Biologics Contract Research Organizations (CRO) Market, By End Use: Movement Analysis
• 8.3. Biologics Contract Research Organizations (CRO) Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 8.4. Large Biopharmaceutical Companies
  • 8.4.1. Large Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Small & Mid-Sized Biopharmaceutical Companies
  • 8.5.1. Small & Mid-Sized Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Others
  • 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Biologics Contract Research Organizations (CRO) Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market Share Analysis, 2024 & 2033
• 9.3. North America
  • 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. U.S
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Competitive Scenario
    • 9.4.8.3. Regulatory Framework
    • 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Competitive Scenario
    • 9.4.9.3. Regulatory Framework
    • 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Australia
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. South Korea
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.4. Saudi Arabia
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.6. Qatar
    • 9.7.6.1. Key Country Dynamics
    • 9.7.6.2. Competitive Scenario
    • 9.7.6.3. Regulatory Framework
    • 9.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.7. Oman
    • 9.7.7.1. Key Country Dynamics
    • 9.7.7.2. Competitive Scenario
    • 9.7.7.3. Regulatory Framework
    • 9.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Key Participant Categorization
  • 10.1.1. Market Leaders
  • 10.1.2. Emerging Players
• 10.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 10.3. Company Profiles
  • 10.3.1. Lonza Group AG
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Performance
    • 10.3.1.3. Service Benchmarking
    • 10.3.1.4. Strategic Initiatives
  • 10.3.2. WuXi Biologics / WuXi AppTec
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Service Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. Samsung Biologics
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Service Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. Catalent, Inc.
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Service Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Fujifilm Diosynth Biotechnologies
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Service Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. AGC Biologics
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Service Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. Thermo Fisher Scientific (Patheon)
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Service Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Boehringer Ingelheim (BioXcellence)
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Service Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Charles River Laboratories
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Service Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Parexel International
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Service Benchmarking
    • 10.3.10.4. Strategic Initiatives
  • 10.3.11. IQVIA
    • 10.3.11.1. Company Overview
    • 10.3.11.2. Financial Performance
    • 10.3.11.3. Service Benchmarking
    • 10.3.11.4. Strategic Initiatives
  • 10.3.12. Medpace Holdings, Inc.
    • 10.3.12.1. Company Overview
    • 10.3.12.2. Financial Performance
    • 10.3.12.3. Service Benchmarking
    • 10.3.12.4. Strategic Initiatives
  • 10.3.13. Syngene International
    • 10.3.13.1. Company Overview
    • 10.3.13.2. Financial Performance
    • 10.3.13.3. Service Benchmarking
    • 10.3.13.4. Strategic Initiatives
  • 10.3.14. Eurofins Scientific
    • 10.3.14.1. Company Overview
    • 10.3.14.2. Financial Performance
    • 10.3.14.3. Service Benchmarking
    • 10.3.14.4. Strategic Initiatives
  • 10.3.15. KBI Biopharma
    • 10.3.15.1. Company Overview
    • 10.3.15.2. Financial Performance
    • 10.3.15.3. Service Benchmarking
    • 10.3.15.4. Strategic Initiatives

관련자료